title: Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia.
authors.forename: A
authors.initials: A
authors.lastname: Buresh
authors.forename: J
authors.initials: J
authors.lastname: Perentesis
authors.forename: L
authors.initials: L
authors.lastname: Rimsza
authors.forename: S
authors.initials: S
authors.lastname: Kurtin
authors.forename: R
authors.initials: R
authors.lastname: Heaton
authors.forename: M
authors.initials: M
authors.lastname: Sugrue
authors.forename: A
authors.initials: A
authors.lastname: List
mesh_terms: D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors; D000970:Antineoplastic Agents / Q000009:adverse effects*; D051231:Farnesyltranstransferase; D006801:Humans; D015477:Leukemia, Myelomonocytic, Chronic / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D007964:Leukocytosis / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D013902:Radiography, Thoracic; D003986:Dibenzocycloheptenes
chemical_list: D019883:Alkyl and Aryl Transferases; D000970:Antineoplastic Agents; D051231:Farnesyltranstransferase; D010880:Piperidines; D011725:Pyridines; C115354:lonafarnib; D003986:Dibenzocycloheptenes